Vitro Biopharma is presently focused on adult stem cells known as mesenchymal stem cells or MSCs. The discovery of embryonic stem cells have shown to be capable of differentiating into any cell type in the body and was largely responsible for the development of modern stem cell technology. Embryonic stem cells are also ethically contentious since, in certain cases, embryo destruction results from the use of embryonic stem cells. However, adult stem cells are derived through non-destructive procedures from a variety of tissue sources. Adult stem cells have been approved for clinical use for over 50 years and have a strong record of safety and efficacy for use in the treatment of numerous blood disorders. Presently, the MSC sector of stem cell research is one of the most rapidly growing and expanding fields within the entire stem cell industry.
The rapid emergence of stem cell products & technology based on MSCs is related to several factors including the widespread availability of these cells from numerous tissue sources and the strong clinical results showing preliminary efficacy and safety in a broad range of indications within disease treatment, recovery from injury and accelerated healing as well as numerous applications in regenerative medicine.